# Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

> **NCT01457430** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 19 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** Icatibant

## Key facts

- **NCT ID:** NCT01457430
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457430, "Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01457430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*